In Vivo

Vertex/J&J: Pushing Big Pharma's Deal Flexibility to the Limit

01 Jul 2006

Vertex Pharmaceuticals deal with Johnson & Johnson for its Phase II hepatitis C protease inhibitor VX-950 underscore the significant potential for HCV protease inhibitors to alter the landscape of disease treatment and suggests pharmaceutical dealmakers will have to be ever more flexible to land biotech's best products.

Just how flexible does a Big Pharma have to be to win an important new drug? Practically contortionary.